Form 4: Edgewise Therapeutics Director Arlene Morris Acquires Stock Options
SEC Form 4 Filing
Director Arlene Morris acquired 34,311 stock options in Edgewise Therapeutics, Inc. on May 6, 2024, according to a Form 4 filing.
Summary
- On May 6, 2024, Arlene Morris, a director of Edgewise Therapeutics, Inc. (EWTX), acquired 34,311 stock options.
- The options have an exercise price of $20.34.
- The options vest monthly, with 1/36th of the shares vesting each month starting June 6, 2024, contingent upon continued service.
- Following the transaction, Morris directly owns 34,311 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, which is a common form of executive compensation in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, aligning management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of transaction: Arlene Morris acquired stock options. |
| 06/06/2024 | Vesting start date: 1/36th of the shares subject to the option vest each month beginning on this date. |
| 05/06/2034 | Expiration date of the stock options. |
| 05/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.